http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 07:18:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MOLECULAR+PARTNERS+AG+++++For%3A+May+30/26579124.html si-local-file:///var/storage/secattach/20260601/26579124.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MOLECULAR+PARTNERS+AG+++++For%3A+May+30/26579124.html Mon, 01 Jun 2026 07:18:00 -0400 MOLN MOLN O.01261731 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MOLECULAR+PARTNERS+AG+++++For%3A+May+30/26579124.html si-local-file:///var/storage/secattach/20260601/26579124.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MOLECULAR+PARTNERS+AG+++++For%3A+May+30/26579124.html Mon, 01 Jun 2026 07:18:00 -0400 MOLN MOLN O.01261731 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MOLECULAR+PARTNERS+AG+++++For%3A+May+30/26579124.html si-local-file:///var/storage/secattach/20260601/26579124.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MOLECULAR+PARTNERS+AG+++++For%3A+May+30/26579124.html Mon, 01 Jun 2026 07:18:00 -0400 MOLN MOLN O.01261731 http://www.streetinsider.com/Earnings/Molecular+Partners+AG+%28MOLN%29+Misses+Q1+EPS+by+28c/26479607.html <p>Molecular Partners AG (NASDAQ: MOLN) reported Q1 EPS of ($0.67), $0.28 worse than the analyst estimate of ($0.39).</p><p>For earnings history and earnings-related data on Molecular Partners AG (MOLN) <a href="http://www.streetinsider.com/ec_earnings.php?q=MOLN">click here</a>.</p> http://www.streetinsider.com/Earnings/Molecular+Partners+AG+%28MOLN%29+Misses+Q1+EPS+by+28c/26479607.html Tue, 12 May 2026 17:46:11 -0400 MOLN http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MOLECULAR+PARTNERS+AG+++++For%3A+Mar+31/26477441.html si-local-file:///var/storage/secattach/20260512/26477441.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MOLECULAR+PARTNERS+AG+++++For%3A+Mar+31/26477441.html Tue, 12 May 2026 16:01:00 -0400 MLLCF MOLN O.01261731 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MOLECULAR+PARTNERS+AG+++++For%3A+Mar+31/26477441.html si-local-file:///var/storage/secattach/20260512/26477441.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MOLECULAR+PARTNERS+AG+++++For%3A+Mar+31/26477441.html Tue, 12 May 2026 16:01:00 -0400 MLLCF MOLN O.01261731 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MOLECULAR+PARTNERS+AG+++++For%3A+Mar+31/26477441.html si-local-file:///var/storage/secattach/20260512/26477441.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MOLECULAR+PARTNERS+AG+++++For%3A+Mar+31/26477441.html Tue, 12 May 2026 16:01:00 -0400 MLLCF MOLN O.01261731 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MOLECULAR+PARTNERS+AG+++++For%3A+May+01/26413094.html si-local-file:///var/storage/secattach/20260501/26413094.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MOLECULAR+PARTNERS+AG+++++For%3A+May+01/26413094.html Fri, 01 May 2026 09:22:00 -0400 MLLCF MOLN O.01261731 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MOLECULAR+PARTNERS+AG+++++For%3A+May+01/26413094.html si-local-file:///var/storage/secattach/20260501/26413094.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MOLECULAR+PARTNERS+AG+++++For%3A+May+01/26413094.html Fri, 01 May 2026 09:22:00 -0400 MLLCF MOLN O.01261731 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MOLECULAR+PARTNERS+AG+++++For%3A+May+01/26413094.html si-local-file:///var/storage/secattach/20260501/26413094.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MOLECULAR+PARTNERS+AG+++++For%3A+May+01/26413094.html Fri, 01 May 2026 09:22:00 -0400 MLLCF MOLN O.01261731 http://www.streetinsider.com/FDA/Molecular+Partners+publishes+phase+1+data+showing+tumor-targeted+therapy/26411806.html <p>Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) published phase 1 clinical data in Nature Cancer for its experimental cancer drug MP0317, according to a company statement.</p> <p>The study involved 46 patients with advanced solid tumors and demonstrated that MP0317 activated CD40 pathways specifically within tumors while showing a favorable safety profile. One patient achieved an unconfirmed partial response and 14 patients experienced stable disease.</p> <p>MP0317 is designed to activate immune cells within the tumor microenvironment by binding to fibroblast activation protein, which is highly expressed in tumor stroma. The drug can be dosed weekly or every three weeks based on its pharmacokinetic http://www.streetinsider.com/FDA/Molecular+Partners+publishes+phase+1+data+showing+tumor-targeted+therapy/26411806.html Fri, 01 May 2026 07:00:37 -0400 A.50216726 MOLN O.01261731 O.21612337 http://www.streetinsider.com/FDA/Molecular+Partners+publishes+phase+1+data+showing+tumor-targeted+therapy/26411806.html <p>Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) published phase 1 clinical data in Nature Cancer for its experimental cancer drug MP0317, according to a company statement.</p> <p>The study involved 46 patients with advanced solid tumors and demonstrated that MP0317 activated CD40 pathways specifically within tumors while showing a favorable safety profile. One patient achieved an unconfirmed partial response and 14 patients experienced stable disease.</p> <p>MP0317 is designed to activate immune cells within the tumor microenvironment by binding to fibroblast activation protein, which is highly expressed in tumor stroma. The drug can be dosed weekly or every three weeks based on its pharmacokinetic http://www.streetinsider.com/FDA/Molecular+Partners+publishes+phase+1+data+showing+tumor-targeted+therapy/26411806.html Fri, 01 May 2026 07:00:37 -0400 A.50216726 MOLN O.01261731 O.21612337 http://www.streetinsider.com/FDA/Molecular+Partners+publishes+phase+1+data+showing+tumor-targeted+therapy/26411806.html <p>Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) published phase 1 clinical data in Nature Cancer for its experimental cancer drug MP0317, according to a company statement.</p> <p>The study involved 46 patients with advanced solid tumors and demonstrated that MP0317 activated CD40 pathways specifically within tumors while showing a favorable safety profile. One patient achieved an unconfirmed partial response and 14 patients experienced stable disease.</p> <p>MP0317 is designed to activate immune cells within the tumor microenvironment by binding to fibroblast activation protein, which is highly expressed in tumor stroma. The drug can be dosed weekly or every three weeks based on its pharmacokinetic http://www.streetinsider.com/FDA/Molecular+Partners+publishes+phase+1+data+showing+tumor-targeted+therapy/26411806.html Fri, 01 May 2026 07:00:37 -0400 A.50216726 MOLN O.01261731 O.21612337 http://www.streetinsider.com/FDA/Molecular+Partners+publishes+phase+1+data+showing+tumor-targeted+therapy/26411806.html <p>Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) published phase 1 clinical data in Nature Cancer for its experimental cancer drug MP0317, according to a company statement.</p> <p>The study involved 46 patients with advanced solid tumors and demonstrated that MP0317 activated CD40 pathways specifically within tumors while showing a favorable safety profile. One patient achieved an unconfirmed partial response and 14 patients experienced stable disease.</p> <p>MP0317 is designed to activate immune cells within the tumor microenvironment by binding to fibroblast activation protein, which is highly expressed in tumor stroma. The drug can be dosed weekly or every three weeks based on its pharmacokinetic http://www.streetinsider.com/FDA/Molecular+Partners+publishes+phase+1+data+showing+tumor-targeted+therapy/26411806.html Fri, 01 May 2026 07:00:37 -0400 A.50216726 MOLN O.01261731 O.21612337 http://www.streetinsider.com/Press+Releases/Molecular+Partners+publishes+Phase+1+MP0317+data+in+Nature+Cancer+demonstrating+tumor-localized+CD40+activation+and+tumor+microenvironment+remodeling/26411784.html <ul><li><em>Positive Phase 1 data confirm MP0317’s tumor-localized CD40 activation with a favorable safety profile in patients with advanced cancer types</em><br/><br/></li><li><em>Pharmacokinetic profile of MP0317 well suited for combination treatment settings, including checkpoint inhibitors</em><br/><br/></li><li><em>Randomized Phase 2 investigator-initiated trial of MP0317 in front-line cholangiocarcinoma open with patient dosing ongoing</em><br/></li></ul> <p>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 01, 2026 (GLOBE NEWSWIRE) --  <strong>Ad hoc announcement pursuant to Art. 53 LR</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KYeL8dCyacHVMkgSYx1UhfqiBoC9-Tk1Y8hMCxcx7Ul7THR2X1bSTejEM2V4W0tMUxdg-7krLTWN7tMelwJOPBgM_wsx_lyB_gKId_npyto=" rel="nofollow" target="_blank">Molecular Partners</a> AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), http://www.streetinsider.com/Press+Releases/Molecular+Partners+publishes+Phase+1+MP0317+data+in+Nature+Cancer+demonstrating+tumor-localized+CD40+activation+and+tumor+microenvironment+remodeling/26411784.html Fri, 01 May 2026 07:00:00 -0400 A.50216726 MOLN MOLN O.01261731 O.21612337 http://www.streetinsider.com/Press+Releases/Molecular+Partners+publishes+Phase+1+MP0317+data+in+Nature+Cancer+demonstrating+tumor-localized+CD40+activation+and+tumor+microenvironment+remodeling/26411784.html <ul><li><em>Positive Phase 1 data confirm MP0317’s tumor-localized CD40 activation with a favorable safety profile in patients with advanced cancer types</em><br/><br/></li><li><em>Pharmacokinetic profile of MP0317 well suited for combination treatment settings, including checkpoint inhibitors</em><br/><br/></li><li><em>Randomized Phase 2 investigator-initiated trial of MP0317 in front-line cholangiocarcinoma open with patient dosing ongoing</em><br/></li></ul> <p>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 01, 2026 (GLOBE NEWSWIRE) --  <strong>Ad hoc announcement pursuant to Art. 53 LR</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KYeL8dCyacHVMkgSYx1UhfqiBoC9-Tk1Y8hMCxcx7Ul7THR2X1bSTejEM2V4W0tMUxdg-7krLTWN7tMelwJOPBgM_wsx_lyB_gKId_npyto=" rel="nofollow" target="_blank">Molecular Partners</a> AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), http://www.streetinsider.com/Press+Releases/Molecular+Partners+publishes+Phase+1+MP0317+data+in+Nature+Cancer+demonstrating+tumor-localized+CD40+activation+and+tumor+microenvironment+remodeling/26411784.html Fri, 01 May 2026 07:00:00 -0400 A.50216726 MOLN MOLN O.01261731 O.21612337 http://www.streetinsider.com/Press+Releases/Molecular+Partners+publishes+Phase+1+MP0317+data+in+Nature+Cancer+demonstrating+tumor-localized+CD40+activation+and+tumor+microenvironment+remodeling/26411784.html <ul><li><em>Positive Phase 1 data confirm MP0317’s tumor-localized CD40 activation with a favorable safety profile in patients with advanced cancer types</em><br/><br/></li><li><em>Pharmacokinetic profile of MP0317 well suited for combination treatment settings, including checkpoint inhibitors</em><br/><br/></li><li><em>Randomized Phase 2 investigator-initiated trial of MP0317 in front-line cholangiocarcinoma open with patient dosing ongoing</em><br/></li></ul> <p>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 01, 2026 (GLOBE NEWSWIRE) --  <strong>Ad hoc announcement pursuant to Art. 53 LR</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KYeL8dCyacHVMkgSYx1UhfqiBoC9-Tk1Y8hMCxcx7Ul7THR2X1bSTejEM2V4W0tMUxdg-7krLTWN7tMelwJOPBgM_wsx_lyB_gKId_npyto=" rel="nofollow" target="_blank">Molecular Partners</a> AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), http://www.streetinsider.com/Press+Releases/Molecular+Partners+publishes+Phase+1+MP0317+data+in+Nature+Cancer+demonstrating+tumor-localized+CD40+activation+and+tumor+microenvironment+remodeling/26411784.html Fri, 01 May 2026 07:00:00 -0400 A.50216726 MOLN MOLN O.01261731 O.21612337 http://www.streetinsider.com/Press+Releases/Molecular+Partners+publishes+Phase+1+MP0317+data+in+Nature+Cancer+demonstrating+tumor-localized+CD40+activation+and+tumor+microenvironment+remodeling/26411784.html <ul><li><em>Positive Phase 1 data confirm MP0317’s tumor-localized CD40 activation with a favorable safety profile in patients with advanced cancer types</em><br/><br/></li><li><em>Pharmacokinetic profile of MP0317 well suited for combination treatment settings, including checkpoint inhibitors</em><br/><br/></li><li><em>Randomized Phase 2 investigator-initiated trial of MP0317 in front-line cholangiocarcinoma open with patient dosing ongoing</em><br/></li></ul> <p>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 01, 2026 (GLOBE NEWSWIRE) --  <strong>Ad hoc announcement pursuant to Art. 53 LR</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KYeL8dCyacHVMkgSYx1UhfqiBoC9-Tk1Y8hMCxcx7Ul7THR2X1bSTejEM2V4W0tMUxdg-7krLTWN7tMelwJOPBgM_wsx_lyB_gKId_npyto=" rel="nofollow" target="_blank">Molecular Partners</a> AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), http://www.streetinsider.com/Press+Releases/Molecular+Partners+publishes+Phase+1+MP0317+data+in+Nature+Cancer+demonstrating+tumor-localized+CD40+activation+and+tumor+microenvironment+remodeling/26411784.html Fri, 01 May 2026 07:00:00 -0400 A.50216726 MOLN MOLN O.01261731 O.21612337 http://www.streetinsider.com/Press+Releases/Molecular+Partners+publishes+Phase+1+MP0317+data+in+Nature+Cancer+demonstrating+tumor-localized+CD40+activation+and+tumor+microenvironment+remodeling/26411784.html <ul><li><em>Positive Phase 1 data confirm MP0317’s tumor-localized CD40 activation with a favorable safety profile in patients with advanced cancer types</em><br/><br/></li><li><em>Pharmacokinetic profile of MP0317 well suited for combination treatment settings, including checkpoint inhibitors</em><br/><br/></li><li><em>Randomized Phase 2 investigator-initiated trial of MP0317 in front-line cholangiocarcinoma open with patient dosing ongoing</em><br/></li></ul> <p>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 01, 2026 (GLOBE NEWSWIRE) --  <strong>Ad hoc announcement pursuant to Art. 53 LR</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KYeL8dCyacHVMkgSYx1UhfqiBoC9-Tk1Y8hMCxcx7Ul7THR2X1bSTejEM2V4W0tMUxdg-7krLTWN7tMelwJOPBgM_wsx_lyB_gKId_npyto=" rel="nofollow" target="_blank">Molecular Partners</a> AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), http://www.streetinsider.com/Press+Releases/Molecular+Partners+publishes+Phase+1+MP0317+data+in+Nature+Cancer+demonstrating+tumor-localized+CD40+activation+and+tumor+microenvironment+remodeling/26411784.html Fri, 01 May 2026 07:00:00 -0400 A.50216726 MOLN MOLN O.01261731 O.21612337 http://www.streetinsider.com/Globe+Newswire/Molecular+Partners+publishes+Phase+1+MP0317+data+in+Nature+Cancer+demonstrating+tumor-localized+CD40+activation+and+tumor+microenvironment+remodeling/26411784.html <ul><li><em>Positive Phase 1 data confirm MP0317’s tumor-localized CD40 activation with a favorable safety profile in patients with advanced cancer types</em><br/><br/></li><li><em>Pharmacokinetic profile of MP0317 well suited for combination treatment settings, including checkpoint inhibitors</em><br/><br/></li><li><em>Randomized Phase 2 investigator-initiated trial of MP0317 in front-line cholangiocarcinoma open with patient dosing ongoing</em><br/></li></ul> <p>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 01, 2026 (GLOBE NEWSWIRE) --  <strong>Ad hoc announcement pursuant to Art. 53 LR</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KYeL8dCyacHVMkgSYx1UhfqiBoC9-Tk1Y8hMCxcx7Ul7THR2X1bSTejEM2V4W0tMUxdg-7krLTWN7tMelwJOPBgM_wsx_lyB_gKId_npyto=" rel="nofollow" target="_blank">Molecular Partners</a> AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), http://www.streetinsider.com/Globe+Newswire/Molecular+Partners+publishes+Phase+1+MP0317+data+in+Nature+Cancer+demonstrating+tumor-localized+CD40+activation+and+tumor+microenvironment+remodeling/26411784.html Fri, 01 May 2026 07:00:00 -0400 A.50216726 MOLN MOLN O.01261731 O.21612337 http://www.streetinsider.com/Globe+Newswire/Molecular+Partners+publishes+Phase+1+MP0317+data+in+Nature+Cancer+demonstrating+tumor-localized+CD40+activation+and+tumor+microenvironment+remodeling/26411784.html <ul><li><em>Positive Phase 1 data confirm MP0317’s tumor-localized CD40 activation with a favorable safety profile in patients with advanced cancer types</em><br/><br/></li><li><em>Pharmacokinetic profile of MP0317 well suited for combination treatment settings, including checkpoint inhibitors</em><br/><br/></li><li><em>Randomized Phase 2 investigator-initiated trial of MP0317 in front-line cholangiocarcinoma open with patient dosing ongoing</em><br/></li></ul> <p>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 01, 2026 (GLOBE NEWSWIRE) --  <strong>Ad hoc announcement pursuant to Art. 53 LR</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KYeL8dCyacHVMkgSYx1UhfqiBoC9-Tk1Y8hMCxcx7Ul7THR2X1bSTejEM2V4W0tMUxdg-7krLTWN7tMelwJOPBgM_wsx_lyB_gKId_npyto=" rel="nofollow" target="_blank">Molecular Partners</a> AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), http://www.streetinsider.com/Globe+Newswire/Molecular+Partners+publishes+Phase+1+MP0317+data+in+Nature+Cancer+demonstrating+tumor-localized+CD40+activation+and+tumor+microenvironment+remodeling/26411784.html Fri, 01 May 2026 07:00:00 -0400 A.50216726 MOLN MOLN O.01261731 O.21612337 http://www.streetinsider.com/Globe+Newswire/Molecular+Partners+publishes+Phase+1+MP0317+data+in+Nature+Cancer+demonstrating+tumor-localized+CD40+activation+and+tumor+microenvironment+remodeling/26411784.html <ul><li><em>Positive Phase 1 data confirm MP0317’s tumor-localized CD40 activation with a favorable safety profile in patients with advanced cancer types</em><br/><br/></li><li><em>Pharmacokinetic profile of MP0317 well suited for combination treatment settings, including checkpoint inhibitors</em><br/><br/></li><li><em>Randomized Phase 2 investigator-initiated trial of MP0317 in front-line cholangiocarcinoma open with patient dosing ongoing</em><br/></li></ul> <p>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 01, 2026 (GLOBE NEWSWIRE) --  <strong>Ad hoc announcement pursuant to Art. 53 LR</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KYeL8dCyacHVMkgSYx1UhfqiBoC9-Tk1Y8hMCxcx7Ul7THR2X1bSTejEM2V4W0tMUxdg-7krLTWN7tMelwJOPBgM_wsx_lyB_gKId_npyto=" rel="nofollow" target="_blank">Molecular Partners</a> AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), http://www.streetinsider.com/Globe+Newswire/Molecular+Partners+publishes+Phase+1+MP0317+data+in+Nature+Cancer+demonstrating+tumor-localized+CD40+activation+and+tumor+microenvironment+remodeling/26411784.html Fri, 01 May 2026 07:00:00 -0400 A.50216726 MOLN MOLN O.01261731 O.21612337 http://www.streetinsider.com/Globe+Newswire/Molecular+Partners+publishes+Phase+1+MP0317+data+in+Nature+Cancer+demonstrating+tumor-localized+CD40+activation+and+tumor+microenvironment+remodeling/26411784.html <ul><li><em>Positive Phase 1 data confirm MP0317’s tumor-localized CD40 activation with a favorable safety profile in patients with advanced cancer types</em><br/><br/></li><li><em>Pharmacokinetic profile of MP0317 well suited for combination treatment settings, including checkpoint inhibitors</em><br/><br/></li><li><em>Randomized Phase 2 investigator-initiated trial of MP0317 in front-line cholangiocarcinoma open with patient dosing ongoing</em><br/></li></ul> <p>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 01, 2026 (GLOBE NEWSWIRE) --  <strong>Ad hoc announcement pursuant to Art. 53 LR</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KYeL8dCyacHVMkgSYx1UhfqiBoC9-Tk1Y8hMCxcx7Ul7THR2X1bSTejEM2V4W0tMUxdg-7krLTWN7tMelwJOPBgM_wsx_lyB_gKId_npyto=" rel="nofollow" target="_blank">Molecular Partners</a> AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), http://www.streetinsider.com/Globe+Newswire/Molecular+Partners+publishes+Phase+1+MP0317+data+in+Nature+Cancer+demonstrating+tumor-localized+CD40+activation+and+tumor+microenvironment+remodeling/26411784.html Fri, 01 May 2026 07:00:00 -0400 A.50216726 MOLN MOLN O.01261731 O.21612337 http://www.streetinsider.com/Globe+Newswire/Molecular+Partners+publishes+Phase+1+MP0317+data+in+Nature+Cancer+demonstrating+tumor-localized+CD40+activation+and+tumor+microenvironment+remodeling/26411784.html <ul><li><em>Positive Phase 1 data confirm MP0317’s tumor-localized CD40 activation with a favorable safety profile in patients with advanced cancer types</em><br/><br/></li><li><em>Pharmacokinetic profile of MP0317 well suited for combination treatment settings, including checkpoint inhibitors</em><br/><br/></li><li><em>Randomized Phase 2 investigator-initiated trial of MP0317 in front-line cholangiocarcinoma open with patient dosing ongoing</em><br/></li></ul> <p>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 01, 2026 (GLOBE NEWSWIRE) --  <strong>Ad hoc announcement pursuant to Art. 53 LR</strong> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KYeL8dCyacHVMkgSYx1UhfqiBoC9-Tk1Y8hMCxcx7Ul7THR2X1bSTejEM2V4W0tMUxdg-7krLTWN7tMelwJOPBgM_wsx_lyB_gKId_npyto=" rel="nofollow" target="_blank">Molecular Partners</a> AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), http://www.streetinsider.com/Globe+Newswire/Molecular+Partners+publishes+Phase+1+MP0317+data+in+Nature+Cancer+demonstrating+tumor-localized+CD40+activation+and+tumor+microenvironment+remodeling/26411784.html Fri, 01 May 2026 07:00:00 -0400 A.50216726 MOLN MOLN O.01261731 O.21612337 http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Molecular+Partners+%28MOLN%29/26346784.html <p>H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $13.00 price target on Molecular Partners (NASDAQ: MOLN).</p><p>The analyst commented: "At the ongoing AACR conference, Molecular Partners presented preclinical data for MP0632 (a logic-gated CD3 Switch-DARPin T cell engager [TCE] that targets mesothelin [MSLN] and EpCAM and is boosted by a CD2-engaging co-stimulatory domain). As shown in the poster presentation, MP0632 selectively kills MSLNxEpCAM co-expressing cells in vitro through its logic-gated design, while activity against single TAA-expressing cells is strongly reduced. Furthermore, this "AND-gate" mechanism enables CD3 engagement only upon simultaneous recognition of both TAAs, resulting in potent cytotoxicity and http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Molecular+Partners+%28MOLN%29/26346784.html Wed, 22 Apr 2026 06:40:25 -0400 MOLN